TrialPloS one2017

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.

Barbara Rossetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.